Studies of human disease in animal models often provide an essential link between chemistry, fundamental research at the molecular level, and the development/evaluation of new diagnostic and therapeutic methods. In our view, integration of these modalities helps to improve data interpretation of optical findings in relation to radionuclide images. We developed a fully integrated multimodal platform that provides complementary registered imaging of bioluminescent, fluorescent, and SPECT signatures in a single scanning session with a single dose of anesthesia. by showing tracer accumulation in non-target organs such as the liver and kidneys (SPECT) and giving a semi-quantitative read-out for tumor spread (bioluminescence). The SPECT and bioluminescence images could be used to place the fluorescence findings in perspective, e.g. ResultsД«oth the phantom and in vivo mouse studies showed that superficial fluorescence signals could be imaged accurately. Bioluminescence imaging (BLI) was compared to the localization of the fluorescence signal in the tumors. A combination of a fluorescent dye and radioactive moiety was used to directly relate the optical images of the module to the SPECT findings. The applicability of the module for bioluminescence and fluorescence imaging was evaluated in both a phantom and in an in vivo setting using mice implanted with a 4 T1-luc + tumor. MethodsДЄn OI module was developed for a preclinical SPECT system (U-SPECT, MILabs, Utrecht, the Netherlands). Next to an optimization in logistics and image fusion, this integration can help improve understanding of the optical imaging (OI) results. In this paper, we introduce a fully integrated bioluminescence-fluorescence-SPECT platform.

However, to date these signatures are evaluated separately on individual preclinical systems. In vivo bioluminescence, fluorescence, and single-photon emission computed tomography (SPECT) imaging provide complementary information about biological processes.

Andor solis background reference